Navigation Links
BioMed Realty Trust Declares Third Quarter 2008 Common Stock and Preferred Stock Dividends
Date:9/15/2008

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its board of directors has declared a third quarter 2008 dividend of $0.335 per share of common stock. The dividend is equivalent to an annualized dividend of $1.34 per common share.

BioMed also announced that its board of directors has declared a dividend of $0.46094 per share of the company's 7.375% Series A Cumulative Redeemable Preferred Stock for the period from July 16, 2008 through October 15, 2008.

The dividends are payable on October 15, 2008 to stockholders of record at the close of business on September 30, 2008.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.9 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at http://www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
2. Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference
3. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
4. Regenesis Biomedical Announces Additions to Board of Directors
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
7. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
8. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
9. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
10. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
11. HIPAA Privacy Rule Impedes Biomedical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ROCHELLE, VIRGINIA (PRWEB) , ... April 27, 2016 ... ... announced today that Jon Clark has joined the company as an Expert Consultant. ... was responsible for industry collaborations and managing the development of small molecule monographs ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on ... of Catherine Moukheibir as Chairman of its Board of Directors. ... Jacques Garaud , who contributed to the rapid development of ... Catherine started her career in strategy consulting and investment ... London .  She held C-Suite level roles in some ...
(Date:4/26/2016)... ... April 26, 2016 , ... Heidelberg Instruments, a ... technology innovation for its Volume Pattern Generator (VPG) line of lithography systems. The ... photomasks as well as a solution for mid volume direct write lithography applications. ...
(Date:4/26/2016)... and MIAMI , ... prize recognizes the innovation capabilities of Norma,s R&D ... benefit patients and laboratory diagnostics globally. ... Norma Instruments , an innovative technology ... the field of hematology, announced today that it ...
Breaking Biology Technology:
(Date:3/10/2016)...   Unisys Corporation (NYSE: UIS ) today ... is testing its biometric identity solution at the Otay Mesa ... help identify certain non-U.S. citizens leaving the country. ... help determine the efficiency and accuracy of using biometric technologies ... run until May 2016. --> the United ...
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI ... categories of Innovation, Research & Development, Leadership in Education, ... This is the 9 th year of the ... of companies and individuals from past years . ... on a pre-described set of criteria, by a panel ...
(Date:3/1/2016)... DUBLIN , March 1, 2016 ... has announced the addition of the  ... 2015-2019"  report to their offering. ... announced the addition of the  "Global ...  report to their offering. ...
Breaking Biology News(10 mins):